Open AccessEscitalopram-induced liver injury: A case report and review of literature
Author(s) -
Qin Xiang Ng,
Christl Suet Kwan Yong,
Wayren Loke,
Wee Song Yeo,
Alex Yu Sen Soh
Publication year - 2019
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v11.i10.719
Subject(s) - escitalopram , medicine , liver injury , citalopram , antidepressant , liver function tests , liver function , asymptomatic , liver disease , serotonin reuptake inhibitor , cholestasis , depression (economics) , gastroenterology , psychiatry , hippocampus , economics , macroeconomics
Depression is a growing public health problem that affects over 350 million people globally and accounts for approximately 7.5% of healthy years lost due to disability. Escitalopram, one of the first-line medications for the treatment of depression, is a selective serotonin reuptake inhibitor and one of the most commonly prescribed antidepressant medications worldwide. Although thought to be generally safe and with minimal drug-drug interactions, we herein present an unusual case of cholestatic liver injury, likely secondary to escitalopram initiation.